CER Daily Newsfeed

Washington DC's 500 Most Influential People of 2026

(5/5, Jacob Raim, Washingtonian) comments “...John M. O'Brien, National Pharmaceutical Council, President and CEO. O'Brien's research convinced advocates and lawmakers that the Inflation Reduction Act's price controls were stifling orphan-drug development—fueling the only bipartisan fix to its health provisions included in last year's reconciliation bill.” Full

How the Waste in Healthcare Drives the U.S. Debt

(5/5, James Weinstein, Los Angeles Times) comments “...The pattern is clear: High-value care is underused, supply drives overuse and preference-sensitive decisions proceed without informed consent — failures that demand better tools to link evidence, capture patient preferences and document decisions at scale. The fixes are clear, too: organized delivery, shared decision-making, comparative-effectiveness research and payment tied to outcomes.” Subscription Required

Most-Favored-Nation Drug Pricing to Save U.S. $529 Billion Over 10 Years, Report Suggests

(5/5, Elias Schisgall, Dow Jones) reports “The Trump administration's efforts to get drug makers to cut prices on new drugs for U.S. patients are expected to generate around $529 billion in domestic savings over the next decade, according to an analysis by the Council of Economic Advisers...‘By tying U.S. drug prices to international prices, prospective MFN will lower U.S. prices and put upward pressure on prices paid in other wealthy nations,’ the Council of Economic Advisers wrote in its report.” Full

Trump's Drugmaker Deals May Save Economy $529B over 10 Years, White House Says

(5/5, Josh Boak, Associated Press) reports “...The scope of the savings claimed by the Trump administration are likely to intensify the scrutiny by Democrats, who counter that any price reductions would be offset by higher costs for prescription drugs not covered by the ‘most favored nation’ framework. One of their main critiques is that pharmaceutical companies have increased their profit margins while working with the administration.” Full

Video: Asembia ASX26: How Payers are Embracing Value-Based Care Models for Cell & Gene Therapies

(5/5, Mike Hollan, Will Shrank, PharmExec) “While advances in cell & gene therapy continue to show promise for creating new treatments, this sector of the industry still faces a major hurdle: the high costs. Whether it’s on the R&D side or delivering and administering the treatment to the patients, cell& gene therapies are expensive. Pharmaceutical Executive spoke with Aradigm Health CEO Will Shrank at the Asembia ASX26 Summit in Las Vegas. During the conversation, he explained the issues the payers face with cell & gene therapies, along with the strategies that the industry is using to move forward with these treatments.” View Video

Ojemda: Publication Of First Ever EU Joint Clinical Assessment Report Is Imminent

(5/5, Francesca Bruce, Pink Sheet) reports “...Ipsen’s Ojemda (tovorafenib) is the subject of the first ever EU-level joint clinical assessment report to be finalized. The report was endorsed just days after the product gained conditional marketing authorization.” Subscription Required